Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | ILK | Q13418 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 9/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645914 | 0.89 | ILK (0.54) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL23645872 | 0.87 | ILK (0.48) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL17077245 | 0.86 | ILK (0.70) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL23645909 | 0.86 | ALOX5 (0.58) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL17085072 | 0.81 | MAPT (0.50) | ALOX5RXRARXRBRXRGILK | |
| SCHEMBL17077237 | 0.79 | ILK (0.62) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9519230 | 0.78 | PTGS2 (0.74) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL9988889 | 0.78 | RXRA (0.66) | PTGS2ALOX5RXRARXRBRXRG | |
| SCHEMBL27333015 | 0.77 | RPA1 (0.72) | PTGS2CA9MALT1PTGS1 | |
| SCHEMBL15556076 | 0.77 | ILK (0.42) | RXRARXRBRXRGILKCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117888-B2 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-09-14 | — | — | US | disclosed |
| US-20210221801-A1 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221801-A1 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | PDK2, PDK3, PDK4 | PTGS2 617/4885ALOX5 4072/4885RXRA 3747/4885 |
| US-11117888-B2 | Irreversible inhibitors of pyruvate kinase M2 and the use thereof | PDK2, PDK3, PDK4 | PTGS2 617/4885ALOX5 4072/4885RXRA 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.